Latest News:
- TIF Position Statement on the Use of DEHP Plasticisers in Medical Devices
- GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (Voxelotor) to Treat Sickle Cell Patients in Europe
- Thalassaemia Prior and Consequent to COVID-19 Pandemic: The Perspective of Thalassaemia International Federation (TIF)
- IMR-687 Receives FDA Orphan Drug Designation for the Treatment of β-Τhalassaemia
- European Commission Approves Reblozyl for the Treatment of Transfusion-dependent β-Thalassaemia
TIF
